Table 4 PHQ-9 and WHODAS outcomes over time and across cohort groups
|  | Control group | Treatment group | adjusted β or RR d (95%CI) | p | ||||
|---|---|---|---|---|---|---|---|---|
N | Mean score (SD) or N (%) | Adjusted mean change (95%CI) from baseline | N | Mean score (SD) or N (%) | Adjusted mean change (95%CI) from baseline | |||
Midline (3 months)a | ||||||||
Response on PHQ-9 b | 209 | 49 (23.4%) | – | 125 | 69 (55.2%) | – | 2.10 (1.53 to 2.88) | < 0.001 |
Remission on PHQ-9 c | 209 | 25 (12.0%) | – | 125 | 40 (32.0%) | – | 2.78 (1.70 to 4.54) | < 0.001 |
PHQ-9 score | 209 | 9.6 (4.66) | -2.63 (− 3.34 to − 1.92) | 125 | 8.0 (6.16) | −5.05 (− 6.02 to − 4.08) | − 2.42 (− 3.49 to − 1.34) | < 0.001 |
WHODAS score | 209 | 34.7 (21.14) | − 4.65 (−8.02 to − 1.28) | 125 | 23.6 (20.99) | − 11.11 (− 15.18 to − 7.05) | − 6.46 (− 11.37 to − 1.55) | 0.010 |
Endline (12 months)a | ||||||||
Response on PHQ-9 b | 195 | 60 (30.8%) | – | 119 | 57 (47.9%) | – | 1.52 (1.13 to 2.05) | 0.006 |
Remission on PHQ-9 c | 195 | 33 (16.9%) | – | 119 | 32 (26.9%) | – | 1.72 (1.11 to 2.68) | 0.016 |
PHQ-9 score | 195 | 9.0 (4.89) | −3.10 (− 3.83 to − 2.37) | 119 | 7.9 (5.17) | −5.07 (− 6.05 to − 4.09) | −1.97 (− 3.04 to − 0.90) | < 0.001 |
WHODAS score | 195 | 31.3 (22.39) | −7.20 (− 10.68 to − 3.73) | 119 | 28.4 (21.64) | −8.00 (− 12.02 to − 3.99) | −0.80 (− 5.68 to 4.07) | 0.746 |